CA2482669A1 - Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine - Google Patents
Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine Download PDFInfo
- Publication number
- CA2482669A1 CA2482669A1 CA002482669A CA2482669A CA2482669A1 CA 2482669 A1 CA2482669 A1 CA 2482669A1 CA 002482669 A CA002482669 A CA 002482669A CA 2482669 A CA2482669 A CA 2482669A CA 2482669 A1 CA2482669 A1 CA 2482669A1
- Authority
- CA
- Canada
- Prior art keywords
- nateglinide
- solvent
- crystal form
- crystals
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 64
- OELFLUMRDSZNSF-OFLPRAFFSA-N (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid Chemical compound C1CC(C(C)C)CCC1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-OFLPRAFFSA-N 0.000 title abstract description 4
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims abstract description 69
- 229960000698 nateglinide Drugs 0.000 claims abstract description 69
- 239000002904 solvent Substances 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 28
- 238000001556 precipitation Methods 0.000 claims abstract description 10
- 239000012453 solvate Substances 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 6
- 238000001816 cooling Methods 0.000 claims abstract description 5
- 238000002844 melting Methods 0.000 claims abstract description 4
- 230000008018 melting Effects 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 239000003973 paint Substances 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 238000002329 infrared spectrum Methods 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 11
- 150000004677 hydrates Chemical class 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- NJSUFZNXBBXAAC-UHFFFAOYSA-N ethanol;toluene Chemical compound CCO.CC1=CC=CC=C1 NJSUFZNXBBXAAC-UHFFFAOYSA-N 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37262502P | 2002-04-15 | 2002-04-15 | |
| US60/372,625 | 2002-04-15 | ||
| PCT/EP2003/003864 WO2003087038A1 (en) | 2002-04-15 | 2003-04-14 | Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2482669A1 true CA2482669A1 (en) | 2003-10-23 |
Family
ID=29250881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002482669A Abandoned CA2482669A1 (en) | 2002-04-15 | 2003-04-14 | Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7247746B2 (enExample) |
| EP (1) | EP1497258A1 (enExample) |
| JP (2) | JP4615866B2 (enExample) |
| CN (1) | CN1304366C (enExample) |
| AU (1) | AU2003242520A1 (enExample) |
| BR (1) | BR0309210A (enExample) |
| CA (1) | CA2482669A1 (enExample) |
| WO (1) | WO2003087038A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861553B2 (en) | 2002-07-03 | 2005-03-01 | Teva Pharmaceuticals Industries Ltd. | Process for preparing nateglinide and intermediates thereof |
| US7420084B2 (en) | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7358390B2 (en) | 2002-07-18 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7148376B2 (en) | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7534913B2 (en) | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
| WO2004020396A1 (en) * | 2002-08-28 | 2004-03-11 | Dr. Reddy's Laboratories Limited | Crystalline form of nateglinide and process for preparation thereof |
| WO2004074330A1 (ja) * | 2003-02-18 | 2004-09-02 | Konishi Co., Ltd. | 硬化性樹脂、その製造方法及び硬化性樹脂組成物 |
| HU227073B1 (hu) * | 2003-07-10 | 2010-06-28 | Richter Gedeon Nyrt | Eljárás királisan tiszta N-(transz-4-izopropil-ciklohexilkarbonil)-D-fenil-alanin (nateglinid) és kristálymódosulatainak elõállítására, valamint a G-kristálymódosulata |
| WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| CN104350041A (zh) | 2012-05-07 | 2015-02-11 | 塞利克斯比奥私人有限公司 | 用于治疗神经系统疾病的组合物和方法 |
| CA2873093A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
| WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
| CN104364230A (zh) * | 2012-05-08 | 2015-02-18 | 塞利克斯比奥私人有限公司 | 用于治疗糖尿病的组合物和方法 |
| WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
| US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
| US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
| US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| SG11201407322QA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of multiple sclerosis |
| NZ701832A (en) | 2012-05-23 | 2016-08-26 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammatory bowel disease |
| WO2013175377A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
| WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
| AU2013311349A1 (en) | 2012-09-08 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of inflammation and lipid disorders |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| AU2014276346A1 (en) | 2013-06-04 | 2015-12-24 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| EP3240779B1 (en) | 2014-09-26 | 2020-10-28 | Cellixbio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| EP3201168B1 (en) | 2014-09-29 | 2020-03-18 | Cellix Bio Private Limited | Compounds and compositions for the treatment of multiple sclerosis |
| EP3212626B1 (en) | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| CN110845355A (zh) | 2015-01-06 | 2020-02-28 | 塞尔利克斯生物私人有限公司 | 用于治疗炎症和疼痛的组合物和方法 |
| CN109100430A (zh) * | 2017-06-20 | 2018-12-28 | 珠海同益制药有限公司 | 一种那格列奈手性异构体色谱分析方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6354321A (ja) * | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
| EP0526171B1 (en) * | 1991-07-30 | 1997-03-05 | Ajinomoto Co., Inc. | Crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and methods for preparing them |
| US5463116A (en) * | 1991-07-30 | 1995-10-31 | Ajinomoto Co., Inc. | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
| EP1435912A4 (en) * | 2001-09-12 | 2005-03-30 | Alembic Ltd | NOVEL STABLE CRYSTAL FORM OF N- (TRANS-4-ISOPROPYLCYCLOHEXYL CARBONYL) -D-PHENYLALANINE AND PREPARATION METHOD THEREOF |
| EP2264004A1 (en) * | 2002-04-15 | 2010-12-22 | Ajinomoto Co., Inc. | New nateglinide crystals |
-
2003
- 2003-04-14 US US10/510,927 patent/US7247746B2/en not_active Expired - Fee Related
- 2003-04-14 CA CA002482669A patent/CA2482669A1/en not_active Abandoned
- 2003-04-14 WO PCT/EP2003/003864 patent/WO2003087038A1/en not_active Ceased
- 2003-04-14 BR BR0309210-0A patent/BR0309210A/pt not_active IP Right Cessation
- 2003-04-14 JP JP2003583994A patent/JP4615866B2/ja not_active Expired - Fee Related
- 2003-04-14 CN CNB038084368A patent/CN1304366C/zh not_active Expired - Lifetime
- 2003-04-14 EP EP03746296A patent/EP1497258A1/en not_active Withdrawn
- 2003-04-14 AU AU2003242520A patent/AU2003242520A1/en not_active Abandoned
-
2007
- 2007-06-20 US US11/765,818 patent/US20080081927A1/en not_active Abandoned
-
2008
- 2008-07-21 US US12/220,061 patent/US20080319222A1/en not_active Abandoned
-
2010
- 2010-07-09 JP JP2010156749A patent/JP2010265295A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20080081927A1 (en) | 2008-04-03 |
| BR0309210A (pt) | 2005-02-09 |
| US7247746B2 (en) | 2007-07-24 |
| US20080319222A1 (en) | 2008-12-25 |
| WO2003087038A1 (en) | 2003-10-23 |
| JP2005522503A (ja) | 2005-07-28 |
| JP4615866B2 (ja) | 2011-01-19 |
| EP1497258A1 (en) | 2005-01-19 |
| CN1646481A (zh) | 2005-07-27 |
| AU2003242520A1 (en) | 2003-10-27 |
| CN1304366C (zh) | 2007-03-14 |
| JP2010265295A (ja) | 2010-11-25 |
| US20050256336A1 (en) | 2005-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7247746B2 (en) | Crystal forms of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine | |
| US5463116A (en) | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them | |
| EP0526171B1 (en) | Crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and methods for preparing them | |
| GB2037754A (en) | Threo - 3 -protected amino - 2 - hydroxy-4oxobutanoic acids or esters, their preparation and their use in the preparation of threo - 3 - amino - 2 - hydroxy-butanoylaminoacetic acids | |
| JP2010090174A (ja) | 新規ナテグリニド結晶 | |
| AU2018371771A1 (en) | Solid state form of Valbenazine | |
| RU2134690C1 (ru) | 5-ацетамидо-2,3,4,5-тетрадеокси-4-гуанидино-d-глицеро-d-галакто-нон-2- енопиранозоновая кислота в кристаллической форме, способы получения, фармацевтическая композиция и способ ее получения | |
| US7977507B2 (en) | Nateglinide crystals | |
| CN105566314A (zh) | 一种盐酸替扎尼定化合物 | |
| CN110372635A (zh) | 氢溴酸沃替西汀α晶型的制备方法 | |
| CN109293548A (zh) | 一种高品质HMG-CoA还原酶抑制剂阿托伐他汀钙的制备方法 | |
| JPH11315088A (ja) | 脂溶性白金（ｉｉ）錯体水和物 | |
| JPH078853B2 (ja) | ドーパミン誘導体の製法 | |
| JP2007510715A (ja) | アトバコンの新規な多形およびその調製のプロセス | |
| CN109535060B (zh) | 一种刺猬通路抑制剂及其制备方法和应用 | |
| WO2001068587A1 (en) | Novel crystal of stilbene derivative and process for producing the same | |
| RU2324676C2 (ru) | Кристаллический n-(транс-4-изопропилциклогексилкарбонил)-d-фенилаланин формы с для лечения сахарного диабета типа 2 и способ его получения | |
| JP3001975B2 (ja) | 結晶性チアガビン塩酸塩−水和物、その製造方法および用途 | |
| CN104844512B (zh) | 一种绿卡色林盐酸盐半水合物晶型的制备方法 | |
| CN104945392A (zh) | 结晶型卡格列净一水合物、制备方法及其应用 | |
| JPH11189584A (ja) | ２−アザビシクロ［２．２．１］ヘプト−５−エン−３−オンの結晶化方法 | |
| FR2521555A1 (fr) | Nouveaux n-((alkylamino) carbonyl) n-(((alkylamino)carbonyl)oxy)-acylamides utiles notamment comme medicaments antineoplasiques | |
| WO2018149327A1 (zh) | 一种卡格列净无定型的制备方法 | |
| Ghosh | Synthesis and Characterization of Polymers Having Steroid Sex Hormones as Pendent Moieties | |
| CN108997465A (zh) | 表没食子儿茶素β-谷甾醇功能分子、制备方法及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |